News | May 31, 2021
Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The GMP certificate is valid for three years until April 2024.
Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The commercial production in the SML was started in November 1989.
The nationwide campaign, running from April 9–23 highlights the first 1,000 days, nutrition, responsive caregiving and play-based learning as critical pillars for children
The study is a global, randomized, double-blind, placebo-controlled trial testing GLM101 for phosphomannomutase 2 congenital disorder of glycosylation
Subscribe To Our Newsletter & Stay Updated
